NICE appraises Xeloda, UFT

The U.K.'s National Institute for Clinical Excellence (NICE) issued guidance on the use of Xeloda capecitabine from Roche (SWX:ROCZ) for breast cancer

Read the full 222 word article

How to gain access

Continue reading with a
two-week free trial.